Terms: = Lung cancer AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL AND Treatment
97 results:
1. Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.
Tan Q; Gao R; Zhang X; Yang J; Xing P; Yang S; Wang D; Wang G; Wang S; Yao J; Zhang Z; Tang L; Yu X; Han X; Shi Y
Cancer Immunol Immunother; 2024 Feb; 73(3):47. PubMed ID: 38349411
[TBL] [Abstract] [Full Text] [Related]
2. [A Case of Gastric cancer with Pulmonary Carcinomatous Lymphangitis and Disseminated Carcinomatosis of the Bone Marrow Responding to S-1 plus Cisplatin Chemotherapy].
Otsuka N; Shirayama K
Gan To Kagaku Ryoho; 2023 Dec; 50(12):1319-1321. PubMed ID: 38247072
[TBL] [Abstract] [Full Text] [Related]
3. Inhalable spray-dried polycaprolactone-based microparticles of Sorafenib Tosylate with promising efficacy on A549 cells.
Yadav KS; Raut HC; Nijhawan HP
Pharm Dev Technol; 2023 Oct; 28(8):755-767. PubMed ID: 37665569
[TBL] [Abstract] [Full Text] [Related]
4. Development and In Vitro Evaluation of Crizotinib-Loaded Lipid-Polymer Hybrid Nanoparticles Using Box-Behnken Design in Non-small Cell lung cancer.
Korucu Aktas P; Baysal I; Yabanoglu-Ciftci S; Arica B
AAPS PharmSciTech; 2023 Sep; 24(7):178. PubMed ID: 37658977
[TBL] [Abstract] [Full Text] [Related]
5. Enzyme/pH dual stimuli-responsive nanoplatform co-deliver disulfiram and doxorubicin for effective treatment of breast cancer lung metastasis.
Xiao P; Tao X; Wang H; Liu H; Feng Y; Zhu Y; Jiang Z; Yin T; Zhang Y; He H; Gou J; Tang X
Expert Opin Drug Deliv; 2023; 20(7):1015-1031. PubMed ID: 37452715
[TBL] [Abstract] [Full Text] [Related]
6. Discovery of novel hypoxia-activated, nitroimidazole constructed multi-target kinase inhibitors on the basis of AZD9291 for the treatment of human lung cancer.
Jia T; Miao R; Zhang J; Zhu H; Zhang C; Zeng L; Zhao Y; Cheng W; Shao J
Bioorg Med Chem; 2023 Aug; 91():117384. PubMed ID: 37356356
[TBL] [Abstract] [Full Text] [Related]
7. Chitosan functionalized pcl nanoparticles bearing tyrosine kinase inhibitor osimertinib mesylate for effective lung cancer therapy.
Dhuri A; Sriram A; Aalhate M; Mahajan S; Parida KK; Singh H; Gupta U; Maji I; Guru SK; Singh PK
Pharm Dev Technol; 2023 Jun; 28(5):460-478. PubMed ID: 37092801
[TBL] [Abstract] [Full Text] [Related]
8. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
9. Ginsenoside Rd ameliorates muscle wasting by suppressing the signal transducer and activator of transcription 3 pathway.
Wijaya YT; Setiawan T; Sari IN; Park K; Lee CH; Cho KW; Lee YK; Lim JY; Yoon JK; Lee SH; Kwon HY
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):3149-3162. PubMed ID: 36127129
[TBL] [Abstract] [Full Text] [Related]
10. Development and Optimization of Osimertinib-loaded Biodegradable Polymeric Nanoparticles Enhance In-vitro Cytotoxicity in Mutant EGFR NSCLC Cell Models and In-vivo Tumor Reduction in H1975 Xenograft Mice Models.
K SK; Choppala AD
AAPS PharmSciTech; 2022 Jun; 23(5):159. PubMed ID: 35676448
[TBL] [Abstract] [Full Text] [Related]
11. Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC.
Tao Z; Kuai X; Wang G; Liu S; Liu K; Zhang H; Xia S; Zhu H
Drug Deliv; 2022 Dec; 29(1):1571-1581. PubMed ID: 35612299
[TBL] [Abstract] [Full Text] [Related]
12. [A prospective cohort study on the clinical value of pelvic peritoneal reconstruction in laparoscopic anterior resection for middle and low rectal cancer].
Ji LQ; Lou Z; Gong HF; Sui JK; Cao FA; Yu GY; Zhu XM; Zheng NX; Meng RG; Zhang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Apr; 25(4):336-341. PubMed ID: 35461202
[No Abstract] [Full Text] [Related]
13. Co-delivery of sorafenib and crizotinib encapsulated with polymeric nanoparticles for the treatment of
Zhong T; Liu X; Li H; Zhang J
Drug Deliv; 2021 Dec; 28(1):2108-2118. PubMed ID: 34607478
[TBL] [Abstract] [Full Text] [Related]
14. Enhancing Targeted cancer treatment by Combining Hyperthermia and Radiotherapy Using Mn-Zn Ferrite Magnetic Nanoparticles.
Wang Y; Zou L; Qiang Z; Jiang J; Zhu Z; Ren J
ACS Biomater Sci Eng; 2020 Jun; 6(6):3550-3562. PubMed ID: 33463170
[TBL] [Abstract] [Full Text] [Related]
15. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.
Qin T; Liu Z; Wang J; Xia J; Liu S; Jia Y; Liu H; Li K
Cancer Biol Med; 2020 Aug; 17(3):753-767. PubMed ID: 32944404
[No Abstract] [Full Text] [Related]
16. Erlotinib-Loaded Poly(ε-Caprolactone) Nanocapsules Improve In Vitro Cytotoxicity and Anticlonogenic Effects on Human A549 lung cancer Cells.
Bruinsmann FA; Buss JH; Souto GD; Schultze E; de Cristo Soares Alves A; Seixas FK; Collares TV; Pohlmann AR; Guterres SS
AAPS PharmSciTech; 2020 Aug; 21(6):229. PubMed ID: 32778976
[TBL] [Abstract] [Full Text] [Related]
17. Investigation of Targeting Relationship between Micro-Rna-22 and vegfr3 in lung Squamous Cell Carcinoma.
Dong Z; Xu QH; Zhu YB; Wang YF; Xiong J; Dang S
Comb Chem High Throughput Screen; 2021; 24(1):148-154. PubMed ID: 32691705
[TBL] [Abstract] [Full Text] [Related]
18. Nanoparticle-Mediated Gene Silencing for Sensitization of lung cancer to Cisplatin Therapy.
Feldmann DP; Heyza J; Zimmermann CM; Patrick SM; Merkel OM
Molecules; 2020 Apr; 25(8):. PubMed ID: 32344513
[TBL] [Abstract] [Full Text] [Related]
19. Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell lung cancer Cells.
Ryu H; Choi HK; Kim HJ; Kim AY; Song JY; Hwang SG; Kim JS; Kim DU; Kim EH; Kim J; Ahn J
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554189
[TBL] [Abstract] [Full Text] [Related]
20. Selective eradication of human non-small cell lung cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo.
Engelberg S; Netzer E; Assaraf YG; Livney YD
Cell Death Dis; 2019 Sep; 10(10):702. PubMed ID: 31541073
[TBL] [Abstract] [Full Text] [Related]
[Next]
